Nucleoside compounds for treating viral infections

Details Nucleoside compounds for treating viral infections Nucleoside compounds for treating viral infections

2006-12-19

2006-12-19

Crane, L. E. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S026230, C536S026260, C536S026700, C536S027200

Reexamination Certificate

active

07151089

ABSTRACT:
Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows:wherein, R, Y, W, W1and W2are as defined herein.

REFERENCES:
patent: 4140851 (1979-02-01), Townsend et al.
patent: 4892865 (1990-01-01), Townsend et al.
patent: 4927830 (1990-05-01), Townsend et al.
patent: 4968686 (1990-11-01), Townsend et al.
patent: 5681941 (1997-10-01), Cook et al.
patent: 5763597 (1998-06-01), Ugarkar et al.
patent: 5798340 (1998-08-01), Bischofberger et al.
patent: 5811534 (1998-09-01), Cook et al.
patent: 5824796 (1998-10-01), Petrie et al.
patent: 5844106 (1998-12-01), Seela et al.
patent: 6004939 (1999-12-01), Chen et al.
patent: 6054442 (2000-04-01), Chen et al.
patent: 6150510 (2000-11-01), Seela et al.
patent: 6211158 (2001-04-01), Seela et al.
patent: 6479651 (2002-11-01), Seela et al.
patent: 6593306 (2003-07-01), Chen et al.
patent: 6777395 (2004-08-01), Bhat et al.
patent: 7094768 (2006-08-01), Roberts et al.
patent: 2002/0035077 (2002-03-01), Tam et al.
patent: 2003/0096981 (2003-05-01), Seela et al.
patent: 2003/0153744 (2003-08-01), Mekouar et al.
patent: 2004/0014108 (2004-01-01), Eldrup et al.
patent: 2004/0014957 (2004-01-01), Eldrup et al.
patent: 2004/0067901 (2004-04-01), Bhat et al.
patent: 2004/0072788 (2004-04-01), Bhat et al.
patent: 61-229897 (1986-10-01), None
patent: WO/1991/10671 (1991-07-01), None
patent: WO/1994/18215 (1994-08-01), None
patent: WO/1994/24144 (1994-10-01), None
patent: WO/1995/07919 (1995-03-01), None
patent: WO/1997/49833 (1997-12-01), None
patent: WO/2001/72764 (2001-10-01), None
patent: WO/2001/90121 (2001-11-01), None
patent: WO/2002/18404 (2002-03-01), None
patent: WO/2002/057287 (2002-07-01), None
patent: WO/2002/057425 (2002-07-01), None
patent: WO/2003/051899 (2003-06-01), None
patent: WO/2003/055896 (2003-07-01), None
patent: WO/2003/061576 (2003-07-01), None
patent: WO/2003/068244 (2003-08-01), None
patent: WO/2004/007512 (2004-01-01), None
patent: WO/2004/011478 (2004-02-01), None
patent: WO/2004/028481 (2004-04-01), None
patent: WO/2004/043977 (2004-05-01), None
Bzowska et al., “7-Deazapurine 2′-deoxyribofuranosides are noncleavable competitive inhibitors ofEscherichia colipurine nucleoside phosphorylase (PNP),”Acta Biochimica Polonica, 45(3);755-768 (1998).
Seela et al., “Pyrrolo[2,3d]Pyrididine Nucleosides: 7-Deaza-2′-Deoxyadenosines,”Nucleosides, Nucleotides&Nucleic Acids, 19(1&2):237-251 (2000).
Migliaccio et al., “Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro”J.Biol.Chem. 278(49):49164-49170 (2003).
Carroll et al., “Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs”J.Biol.Chem278(14):11979-11981 (2003).
Seela et al, “Oligonucleoties containing 7-deazaadenines: the influence of the 7-substituent chain length and charge on the duplex stability,”Helvetica Cimica Acta., 82(11):1878-1898 (1999).
Rosemeyer, et al., “Stereoelectronic effects of modified purine bases on the sugar conformation of nucleosides: pyrrolo[2,3-d] pyrimidines,”Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry, 11:2341-2346 (1997).
Rosemeyer, et al., “Steric and stereoelectronic effects of 7-deazapurine bases on the sugar conformation of 2′-deoxynucleosides”Nucleosides&Nucleotides16(7-9) 1447-1451 (1997).
Rosemeyer, et al., “Stereoelectronic effects of modified purines on the sugar conformation of nucleosides and fluorescence properties,”Nucleosides&Nucleotides, 16(5&6):821-828 (1997).
Seela, et al., “Palladium-catalyzed cross coupling of 7-iodo-2′-deoxytubercidin with terminal alkynes”Synthesis6:726-730 (1996).
Schneller, et al., “Biological Activity and a modified synthesis of 8-Amino-3-β-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, and isomer of formycin,”J. Med Chem.27, 924-928 (1984).
Giziewicz, et al., “Antiviral and antimetabolic activities of formycin and its N-, N2-, 2′-O- and 3′-O-methylated derivatives,”Biochemical Pharmacology24, 1813-1817, (1975).
Bergstrom, et al., Pyrrolo[2,3-d]pyrimidine Nucleoside Antibiotic Analogues. Synthesis via Organopalladium Intermediates Derived from 5-Mercuritubercidin,J. Org Chem.46:1423-1431 (1981).
Bergstrom, et al., Antiviral Activity of C-5 Substituted Tubercidin Analogues,J. Med. Chem.27:285-292 (1984).
Sharma, et al., “Synthesis of 5′-Substituted Derivatives of the Pyrrolo [2,3-d]-Pyrimidine Nucleoside Sangivamycin and their Effect on Protein Kinase A and C Activity,”Nucleosides&Nucleotides12(3&4) 295-304 (1993).
Müller, et al., “7-Deaza-2-phenyladenines: Structure-Activity Relationship of Potent A1 Selective Adenosine Receptor Antogonists” J. Med. Chem. 33:2822-2828 (1990).
Limori, et al. “2′-C-, 3′-C- and 5′-C-Methylsangivamycins: Conformational Lock With The Methyl Group,” Tetrahedrom Letters 32(49) 7273-7276 (1991).
Kondo, et al., “Synthesis of 5-Methyltubercidin and Its a-Anomer via Condensation of the Anion of 4-Methoxy-5-methyl-2-methylthiopyrrolo [2, 3-d] pyrimidine and 2, 3,5-Tri-O-benzyl-D-ribofuranosyl Bromide,”Agric.Biol.Chem.41(8):1501-1507 (1977).
Uematsu, et al., “5-Hydroxymethyltubercidin, Synthesis, Biological Activity, and Role in Pyrrolopyrimidine Biosynthesis,” J. of Med.Chem, 16(12):1405-1407(1973).
Schram, et al., “Pyrrolopyrimidine Nucleosides VIII. Synthesis of Sangivamycin Derivatives possessing exocyclic heterocycles at C 5”J. Carbohydrates, Nucleosides, Nucleotides1(1):39-54 (1974).
Bergstrom et al.; “Antiviral Activity of C-5 Substituted Tubercidin Analogues,”J. Med. Chem., 27:285-292 (1984).
DeClercq, et al., “Nucleic Acid Related Compounds. 51. Synthesis and Biological Properties of Sugar-Modified Analogues of Nucleoside Antibiotics Tubercidin, Toyocamycin, Sangivamycin, and Formycin”,J. Med.Chem.30:481-486 (1987).
Hobbs, F.W., Jr., Palladium-Catalyzed Synthesis of Alkynylamino Nucleosides. A Universal Linker for Nucleic Acids,J. Org. Chem., 54:3420-3422 (1989).
Murai et al. “A Synthesis and an X-Ray Analysis 2′-C,3′-C- And 5′-C-Methylsangivamcyins”Heterocycles33:391-404 (1992).
Beigelman et al. “New Syntheses of 2′-C-Methylnucleosides Starting from D-Glucose and D-Ribose”Carbo Research, 166:219-232 (1987).

Affiliated with

Also associated with

Rating

Nucleoside compounds for treating viral infections does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleoside compounds for treating viral infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside compounds for treating viral infections will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3671889